AstraZeneca AZN and its Japanese partner Daiichi Sankyo announced that the FDA has granted a Breakthrough Therapy designation ...

Limited (HCM) announced that the Center for Drug Evaluation of Chinas National Medical Products Administration or ...

Scientists are making waves with a novel therapy for metastatic colorectal cancer (mCRC) that combines two powerful antibodies—one targeting epidermal growth factor receptor (EGFR), the other ...

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological disea ...

Among Taiwan’s non-small cell lung cancer cases, approximately 55 percent involve an EGFR mutation, with deletion of exon 19 and exon 21 the most common mutations, treatable with first to ...

Study demonstrates how metabolic imaging differentiates high and low oxidative phosphorylation (OXPHOS) subtypes of ...

US FDA grants breakthrough therapy designation to datopotamab deruxtecan for patients with previously treated advanced EGFR-mutated NSCLC: Cambridge, UK Tuesday, December 10, 2024 ...

Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: Rare NRG1 Fusion Therapeutics ...

Datopotamab deruxtecan (Dato-DXd) has been granted Breakthrough Therapy designation (BTD) by the US Food and Drug ...

Datopotamab deruxtecan has been granted Breakthrough Therapy Designation, or BTD, in the U.S. for the treatment of adult patients with locally ...